Market Place
Sourcing Support
IPSEN - Buy-Back Programme - Art 5 Of MAR - Week 22 - 2026
01 Jun 2026 //
GLOBENEWSWIRE
Ipsen Announces The Launch Of An Employee Shareholding Plan
29 May 2026 //
GLOBENEWSWIRE
New Data Reinforces IQIRVO`s Impact on ALP and Fatigue in PBC
28 May 2026 //
GLOBENEWSWIRE
Ipsen Share Buyback Programme - Art. 5 MAR - Week 21 2026
27 May 2026 //
GLOBENEWSWIRE
Young People Unprepared for Adult Healthcare Transition
20 May 2026 //
PHARMIWEB
Ipsen Presents First Head-to-Head Dysport vs. Botox Data
19 May 2026 //
GLOBENEWSWIRE
Transcat to Host Q4 FY2026 Conference Call and Webcast on May 26
18 May 2026 //
GLOBENEWSWIRE
Ipsen Initiates A New Share Buy-Back Program
18 May 2026 //
GLOBENEWSWIRE
Ipsen Unveils Phase II Corabotase Data: Prolonged Efficacy
17 May 2026 //
PRESS RELEASE
Annual General Meeting Of Ipsen S.A. Held On 13 May 2026
13 May 2026 //
GLOBENEWSWIRE
Ipsen S.A. Evolves Board Composition
13 May 2026 //
GLOBENEWSWIRE
Ipsen Reports Strong Q1 Sales, Affirms Full-Year Outlook
23 Apr 2026 //
GLOBENEWSWIRE
Ipsen Shares Information for May 13 Shareholders` Meeting
22 Apr 2026 //
GLOBENEWSWIRE
Ojemda Approved 1st EU Targeted Therapy in Pediatric LLG Glioma
22 Apr 2026 //
GLOBENEWSWIRE
Ipsen’s Ojemda Receives Approval in Europe
20 Apr 2026 //
EMA
Ipsen Announces Beech Tree`s Exemption From Public Tender Offer
03 Apr 2026 //
GLOBENEWSWIRE
Ipsen Releases 2025 Universal Registration Document
01 Apr 2026 //
GLOBENEWSWIRE
Ipsen Highlights Early Immuno-Oncology Pipeline At AACR
18 Mar 2026 //
GLOBENEWSWIRE
Ipsen Reports February 2026 Voting Rights And Share Capital
13 Mar 2026 //
GLOBENEWSWIRE
Ipsen Names Michelle C. Werner EVP, North America President
12 Mar 2026 //
GLOBENEWSWIRE
Ipsen Withdraws Tazverik In Lymphoma And Sarcoma
10 Mar 2026 //
GLOBENEWSWIRE
HUTCHMED Updates On TAZVERIK Oncology Product In China
09 Mar 2026 //
GLOBENEWSWIRE
Ipsen Receives Positive CHMP Opinion for Ojemda
27 Feb 2026 //
GLOBENEWSWIRE
Quotient Sciences Extends Mfg Partnership For Ultra-Rare Disease
27 Feb 2026 //
PRESS RELEASE
Ipsen S.A. Publishes Its 2025 Consolidated Financial Statements
19 Feb 2026 //
GLOBENEWSWIRE
Ipsen Reports Strong 2025 Results, Offers 2026 Guidance
12 Feb 2026 //
GLOBENEWSWIRE
Ipsen`s Iqirvo Sales Hit $200M; GENFIT Gets $20M Milestone
12 Feb 2026 //
GLOBENEWSWIRE
Ipsen Reports January 2026 Voting Rights And Share Capital
09 Feb 2026 //
GLOBENEWSWIRE
Origami Pharma Teams Up With Ipsen For Protein Degrader Program
30 Jan 2026 //
BUSINESSWIRE
Ipsen Nominates Peter Guenter To Its Board Of Directors
29 Jan 2026 //
GLOBENEWSWIRE
Pierrick Appoint as Executive Vice President Technical Operations
27 Jan 2026 //
GLOBENEWSWIRE
Galderma Updates Neuromodulator R&D Partnership Arbitration Case
21 Jan 2026 //
BUSINESSWIRE
Ipsen Strengthens Commitment To Neurological Disease Solutions
14 Jan 2026 //
GLOBENEWSWIRE
FDA Grants Ipsen BTD for IPN60340 in Acute Myeloid Leukemia
13 Jan 2026 //
GLOBENEWSWIRE
Ipsen Reports December 2025 Voting Rights And Share Capital
07 Jan 2026 //
GLOBENEWSWIRE
Ipsen Half-Year Statement – 31 December 2025
06 Jan 2026 //
GLOBENEWSWIRE
Ipsen`s ADC push leads to $1B deal for preclinical Simcere drug
27 Dec 2025 //
GLOBENEWSWIRE
Ipsen Fails to Land Pivotal Rare Disease Trial
20 Dec 2025 //
FIERCE BIOTECH
Ipsen Acquires Imcheck Therapeutics, Expands Oncology Pipeline
15 Dec 2025 //
GLOBENEWSWIRE
Ipsen Buy-Back Programme: Art. 5 MAR - Week 49, 2025
09 Dec 2025 //
GLOBENEWSWIRE
Ipsen Reports November 2025 Voting Rights And Share Capital
08 Dec 2025 //
GLOBENEWSWIRE
Ipsen Provides Update On Legacy Of Henri Beaufour
05 Dec 2025 //
GLOBENEWSWIRE
Ipsen Buy-Back Programme: Art. 5 MAR - Week 48, 2025
02 Dec 2025 //
GLOBENEWSWIRE
Ipsen Mourns Passing Of Founding Family Board Member Henri
01 Dec 2025 //
GLOBENEWSWIRE
Ipsen Share Buyback: MAR Article 5, Week 47 2025
25 Nov 2025 //
GLOBENEWSWIRE
Ipsen Buy-Back Programme: Art. 5 MAR, Week 46 2025
19 Nov 2025 //
GLOBENEWSWIRE
IPSEN - Buy-Back Programme - Art 5 Of MAR - Week 45 - 2025
12 Nov 2025 //
GLOBENEWSWIRE
Ipsen To Present Late-Breaking AASLD Sessions On Iqirvo in PBC
07 Nov 2025 //
GLOBENEWSWIRE
Ipsen Reports October 2025 Voting Rights And Share Capital
07 Nov 2025 //
GLOBENEWSWIRE
IPSEN - Buy-Back Programme - Art 5 Of MAR - Week 44 - 2025
06 Nov 2025 //
GLOBENEWSWIRE
IPSEN - Buy-Back Programme - Art 5 Of MAR - Week 43 - 2025
28 Oct 2025 //
GLOBENEWSWIRE
Ipsen Initiative Guides Young Adults Aging Out Of Pediatric Care
24 Oct 2025 //
FIERCE PHARMA
Ipsen Puts up $1.6B to Absorb ImCheck for Leukemia Antibody
24 Oct 2025 //
BIOSPACE
Ipsen Boosts Full-Year Guidance After Strong 9-Month Sales
22 Oct 2025 //
GLOBENEWSWIRE
IPSEN - Buy-Back Programme - Art 5 Of MAR - Week 42 - 2025
21 Oct 2025 //
GLOBENEWSWIRE
DETERA Therapeutics Wins The Ipsen Golden Ticket 2025
15 Oct 2025 //
GLOBENEWSWIRE
IPSEN - Buy-Back Programme - Art 5 Of MAR - Week 41 - 2025
15 Oct 2025 //
GLOBENEWSWIRE
Ipsen Reports September 2025 Voting Rights And Share Capital
07 Oct 2025 //
GLOBENEWSWIRE
IPSEN - Buy-Back Programme - Art 5 Of MAR - Week 40 - 2025
07 Oct 2025 //
GLOBENEWSWIRE
Ipsen - Buy-Back Programme - Art 5 Of Mar - Week 39 - 2025
30 Sep 2025 //
GLOBENEWSWIRE
